Antibody treatment for deadly skin infections
Researcher
Dr. Sarah Hobdey
Idaho Veterans Research and Education Foundation
Boise VA Medical Center
Status
In Review
Time remaining
Funding closed
About this study
Group A Streptococcus (GAS or Streptococcus pyogenes) is a bacteria that ranks among the top 10 causes of infection-associated death worldwide. Necrotizing soft tissue infections (NSTIs) are one of the most severe and life-threatening infections from this bacteria and lead to rapidly progressive death of skin and underlying tissue. Even with antibiotics and optimal care, one-quarter of NSTIs result in death. The major mechanism for this infection is through a toxin released by GAS. Through this study, we aim to engineer an antibody which will bind and effectively neutralize the GAS toxin thereby slowing or even progression of infection. We hope that this antibody could be given to infected patients along with standard antibiotics and supportive care to reduce death and disability.
Significance
Researcher's story
Contributions
-
-
-

-
funded
-
raised
-
goal
-
Subscribe to updates on this research
Favorite this research
Grant-based funding
Gift-based funding